Compare DBD & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DBD | XNCR |
|---|---|---|
| Founded | 1859 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2023 | 2013 |
| Metric | DBD | XNCR |
|---|---|---|
| Price | $52.02 | $33.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $85.00 | $43.83 |
| AVG Volume (30 Days) | 343.9K | ★ 1.5M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 677.27 | 65.36 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $3,805,700,000.00 | $125,576,000.00 |
| Revenue This Year | $1.93 | $58.19 |
| Revenue Next Year | $2.54 | N/A |
| P/E Ratio | $65.29 | ★ N/A |
| Revenue Growth | 1.46 | ★ 13.65 |
| 52 Week Low | $49.77 | $10.38 |
| 52 Week High | $92.09 | $40.60 |
| Indicator | DBD | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 32.61 | 54.03 |
| Support Level | N/A | $22.80 |
| Resistance Level | $85.54 | $33.60 |
| Average True Range (ATR) | 2.43 | 2.08 |
| MACD | -0.50 | -0.54 |
| Stochastic Oscillator | 18.84 | 35.21 |
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.